Vical, Inc. (NASDAQ:VICL)

CAPS Rating: 4 out of 5

The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Recs

2
Player Avatar zzlangerhans (99.80) Submitted: 10/1/2011 7:59:32 PM : Outperform Start Price: $2.48 VICL Score: +42.68

Everyone wants to believe that when the release date for topline data in a phase III cancer trial keeps getting pushed back further and further, it means patients receiving the study drug are living longer. I guess if anyone ever actually finds the cure for cancer, the topline data won't be released until the study participants die of other causes.

You might have noticed I'm a little skeptical about the prospects for Allovectin-7 in phase III. But after making about nine grand on Vical's last upward run, it pays for me to keep a close eye on this stock. And the fact is that Vical is in a fairly good position to repeat history next spring if they don't postpone the end of the trial yet again. Of course, it's way too early to buy in again for real.

Member Avatar siri22 (< 20) Submitted: 11/9/2011 1:51:32 AM
Recs: 0

Red and green?

Featured Broker Partners


Advertisement